Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Tobias BANASCHEWSKI |
Documents disponibles écrits par cet auteur (46)
Faire une suggestion Affiner la recherche
Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial / D. PURPER-OUAKIL in Journal of Child Psychology and Psychiatry, 63-2 (February 2022)
[article]
Titre : Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial Type de document : Texte imprimé et/ou numérique Auteurs : D. PURPER-OUAKIL, Auteur ; H. BLASCO-FONTECILLA, Auteur ; T. ROS, Auteur ; Eric ACQUAVIVA, Auteur ; Tobias BANASCHEWSKI, Auteur ; Sarah BAUMEISTER, Auteur ; E. BOUSQUET, Auteur ; A. BUSSALB, Auteur ; M. DELHAYE, Auteur ; R. DELORME, Auteur ; R. DRECHSLER, Auteur ; A. GOUJON, Auteur ; A. HÄGE, Auteur ; A. KAISER, Auteur ; L. MAYAUD, Auteur ; K. MECHLER, Auteur ; C. MENACHE, Auteur ; O. REVOL, Auteur ; F. TAGWERKER, Auteur ; S. WALITZA, Auteur ; A. M. WERLING, Auteur ; S. BIOULAC, Auteur ; Daniel BRANDEIS, Auteur Article en page(s) : p.187-198 Langues : Anglais (eng) Mots-clés : Attention-deficit hyperactivity disorder methylphenidate neurofeedback randomized clinical trial Index. décimale : PER Périodiques Résumé : BACKGROUND: Neurofeedback is considered a promising intervention for the treatment of attention-deficit hyperactivity disorder (ADHD). NEWROFEED is a prospective, multicentre, randomized (3:2), reference drug-controlled trial in children with ADHD aged between 7 and 13?years. The main objective of NEWROFEED was to demonstrate the noninferiority of personalized at-home neurofeedback (NF) training versus methylphenidate in the treatment of children with ADHD. METHODS: The NF group (n?=?111) underwent eight visits and two treatment phases of 16 to 20 at-home sessions with down-training of the theta/beta ratio (TBR) for children with high TBR and enhancing the sensorimotor rhythm (SMR) for the others. The control group (n?=?67) received optimally titrated long-acting methylphenidate. The primary endpoint was the change between baseline and endpoint in the Clinician ADHD-RS-IV total score in the per-protocol population (90 NF/59 controls). TRIAL REGISTRATION: US National Institute of Health, ClinicalTrials.gov #NCT02778360. RESULTS: Our study failed to demonstrate noninferiority of NF versus methylphenidate (mean between-group difference 8.09 90% CI [8.09; 10.56]). However, both treatment groups showed significant pre-post improvements in core ADHD symptoms and in a broader range of problems. Reduction in the Clinician ADHD-RS-IV total score between baseline and final visit (D90) was 26.7% (SMD?=?0.89) in the NF and 46.9% (SMD?=?2.03) in the control group. NF effects increased whereas those of methylphenidate were stable between intermediate and final visit. CONCLUSIONS: Based on clinicians' reports, the effects of at-home NF were inferior to those of methylphenidate as a stand-alone treatment. En ligne : http://dx.doi.org/10.1111/jcpp.13462 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=457
in Journal of Child Psychology and Psychiatry > 63-2 (February 2022) . - p.187-198[article] Personalized at-home neurofeedback compared to long-acting methylphenidate in children with ADHD: NEWROFEED, a European randomized noninferiority trial [Texte imprimé et/ou numérique] / D. PURPER-OUAKIL, Auteur ; H. BLASCO-FONTECILLA, Auteur ; T. ROS, Auteur ; Eric ACQUAVIVA, Auteur ; Tobias BANASCHEWSKI, Auteur ; Sarah BAUMEISTER, Auteur ; E. BOUSQUET, Auteur ; A. BUSSALB, Auteur ; M. DELHAYE, Auteur ; R. DELORME, Auteur ; R. DRECHSLER, Auteur ; A. GOUJON, Auteur ; A. HÄGE, Auteur ; A. KAISER, Auteur ; L. MAYAUD, Auteur ; K. MECHLER, Auteur ; C. MENACHE, Auteur ; O. REVOL, Auteur ; F. TAGWERKER, Auteur ; S. WALITZA, Auteur ; A. M. WERLING, Auteur ; S. BIOULAC, Auteur ; Daniel BRANDEIS, Auteur . - p.187-198.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 63-2 (February 2022) . - p.187-198
Mots-clés : Attention-deficit hyperactivity disorder methylphenidate neurofeedback randomized clinical trial Index. décimale : PER Périodiques Résumé : BACKGROUND: Neurofeedback is considered a promising intervention for the treatment of attention-deficit hyperactivity disorder (ADHD). NEWROFEED is a prospective, multicentre, randomized (3:2), reference drug-controlled trial in children with ADHD aged between 7 and 13?years. The main objective of NEWROFEED was to demonstrate the noninferiority of personalized at-home neurofeedback (NF) training versus methylphenidate in the treatment of children with ADHD. METHODS: The NF group (n?=?111) underwent eight visits and two treatment phases of 16 to 20 at-home sessions with down-training of the theta/beta ratio (TBR) for children with high TBR and enhancing the sensorimotor rhythm (SMR) for the others. The control group (n?=?67) received optimally titrated long-acting methylphenidate. The primary endpoint was the change between baseline and endpoint in the Clinician ADHD-RS-IV total score in the per-protocol population (90 NF/59 controls). TRIAL REGISTRATION: US National Institute of Health, ClinicalTrials.gov #NCT02778360. RESULTS: Our study failed to demonstrate noninferiority of NF versus methylphenidate (mean between-group difference 8.09 90% CI [8.09; 10.56]). However, both treatment groups showed significant pre-post improvements in core ADHD symptoms and in a broader range of problems. Reduction in the Clinician ADHD-RS-IV total score between baseline and final visit (D90) was 26.7% (SMD?=?0.89) in the NF and 46.9% (SMD?=?2.03) in the control group. NF effects increased whereas those of methylphenidate were stable between intermediate and final visit. CONCLUSIONS: Based on clinicians' reports, the effects of at-home NF were inferior to those of methylphenidate as a stand-alone treatment. En ligne : http://dx.doi.org/10.1111/jcpp.13462 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=457 Practice Tools for Screening and Monitoring Insomnia in Children and Adolescents with Autism Spectrum Disorder / Tobias BANASCHEWSKI in Journal of Autism and Developmental Disorders, 52-8 (August 2022)
[article]
Titre : Practice Tools for Screening and Monitoring Insomnia in Children and Adolescents with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Tobias BANASCHEWSKI, Auteur ; Oliviero BRUNI, Auteur ; Joaquin FUENTES, Auteur ; Catherine Mary HILL, Auteur ; Allan HVOLBY, Auteur ; Maj-Britt POSSERUD, Auteur ; Carmen SCHRODER, Auteur Article en page(s) : p.3758-3768 Langues : Anglais (eng) Mots-clés : Adolescent Autism Spectrum Disorder/epidemiology Child Humans Mass Screening/methods Sleep Initiation and Maintenance Disorders/diagnosis Child Adolescent Sleep Insomnia Autism spectrum disorder ASD Index. décimale : PER Périodiques Résumé : Between 50-80% of children with autism spectrum disorder (ASD) have insomnia, which adversely affects their mental and physical health. However, there is no consensus to-date on suitable tools for insomnia screening and monitoring in daily clinical practice. An expert panel of child neuropsychiatry and sleep specialists, with expertise in children with neurodevelopmental disabilities, recommends: (1) performing insomnia screening of all children with ASD; (2) considering discussion or referral to a sleep specialist when comorbid sleep disorders are suspected. The panel further developed structured, brief screening and monitoring tools to facilitate insomnia screening and management in daily practice, monitor treatment effectiveness and standardize and compare outcomes across clinical settings to improve care and well-being of children with ASD and their families. En ligne : http://dx.doi.org/10.1007/s10803-021-05236-w Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=485
in Journal of Autism and Developmental Disorders > 52-8 (August 2022) . - p.3758-3768[article] Practice Tools for Screening and Monitoring Insomnia in Children and Adolescents with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Tobias BANASCHEWSKI, Auteur ; Oliviero BRUNI, Auteur ; Joaquin FUENTES, Auteur ; Catherine Mary HILL, Auteur ; Allan HVOLBY, Auteur ; Maj-Britt POSSERUD, Auteur ; Carmen SCHRODER, Auteur . - p.3758-3768.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-8 (August 2022) . - p.3758-3768
Mots-clés : Adolescent Autism Spectrum Disorder/epidemiology Child Humans Mass Screening/methods Sleep Initiation and Maintenance Disorders/diagnosis Child Adolescent Sleep Insomnia Autism spectrum disorder ASD Index. décimale : PER Périodiques Résumé : Between 50-80% of children with autism spectrum disorder (ASD) have insomnia, which adversely affects their mental and physical health. However, there is no consensus to-date on suitable tools for insomnia screening and monitoring in daily clinical practice. An expert panel of child neuropsychiatry and sleep specialists, with expertise in children with neurodevelopmental disabilities, recommends: (1) performing insomnia screening of all children with ASD; (2) considering discussion or referral to a sleep specialist when comorbid sleep disorders are suspected. The panel further developed structured, brief screening and monitoring tools to facilitate insomnia screening and management in daily practice, monitor treatment effectiveness and standardize and compare outcomes across clinical settings to improve care and well-being of children with ASD and their families. En ligne : http://dx.doi.org/10.1007/s10803-021-05236-w Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=485 Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents / Samuele CORTESE in Journal of Child Psychology and Psychiatry, 54-3 (March 2013)
[article]
Titre : Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents Type de document : Texte imprimé et/ou numérique Auteurs : Samuele CORTESE, Auteur ; Martin HOLTMANN, Auteur ; Tobias BANASCHEWSKI, Auteur ; Jan K. BUITELAAR, Auteur ; David R. COGHILL, Auteur ; Marina DANCKAERTS, Auteur ; Ralf W. DITTMANN, Auteur ; John GRAHAM, Auteur ; Eric TAYLOR, Auteur ; Joseph A. SERGEANT, Auteur ; Adhd Guidelines Group ON BEHALF OF THE EUROPEAN, Auteur Article en page(s) : p.227-246 Mots-clés : ADHD medication adverse events management recommendations European Index. décimale : PER Périodiques Résumé : Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD. Methods: For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system. Results: The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms. Conclusion: Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12036 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=191
in Journal of Child Psychology and Psychiatry > 54-3 (March 2013) . - p.227-246[article] Practitioner Review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents [Texte imprimé et/ou numérique] / Samuele CORTESE, Auteur ; Martin HOLTMANN, Auteur ; Tobias BANASCHEWSKI, Auteur ; Jan K. BUITELAAR, Auteur ; David R. COGHILL, Auteur ; Marina DANCKAERTS, Auteur ; Ralf W. DITTMANN, Auteur ; John GRAHAM, Auteur ; Eric TAYLOR, Auteur ; Joseph A. SERGEANT, Auteur ; Adhd Guidelines Group ON BEHALF OF THE EUROPEAN, Auteur . - p.227-246.
in Journal of Child Psychology and Psychiatry > 54-3 (March 2013) . - p.227-246
Mots-clés : ADHD medication adverse events management recommendations European Index. décimale : PER Périodiques Résumé : Background: Medication is an important element of therapeutic strategies for ADHD. While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs. The aim of this review is to provide evidence- and expert-based guidance concerning the management of (AEs) with medications for ADHD. Methods: For ease of use by practitioners and clinicians, the article is organized in a simple question and answer format regarding the prevalence and management of the most common AEs. Answers were based on empirical evidence from studies (preferably meta-analyses or systematic reviews) retrieved in PubMed, Ovid, EMBASE and Web of Knowledge through 30 June 2012. When no empirical evidence was available, expert consensus of the members of the European ADHD Guidelines Group is provided. The evidence-level of the management recommendations was based on the SIGN grading system. Results: The review covers monitoring and management strategies of loss of appetite and growth delay, cardiovascular risks, sleep disturbance, tics, substance misuse/abuse, seizures, suicidal thoughts/behaviours and psychotic symptoms. Conclusion: Most AEs during treatment with drugs for ADHD are manageable and most of the times it is not necessary to stop medication, so that patients with ADHD may continue to benefit from the effectiveness of pharmacological treatment. En ligne : http://dx.doi.org/10.1111/jcpp.12036 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=191 Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder / David DALEY in Journal of Child Psychology and Psychiatry, 59-9 (September 2018)
[article]
Titre : Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder Type de document : Texte imprimé et/ou numérique Auteurs : David DALEY, Auteur ; Saskia VAN DER OORD, Auteur ; Maite FERRIN, Auteur ; Samuele CORTESE, Auteur ; Marina DANCKAERTS, Auteur ; Manfred DOEPFNER, Auteur ; Barbara J. VAN DEN HOOFDAKKER, Auteur ; David COGHILL, Auteur ; Margaret THOMPSON, Auteur ; Philip ASHERSON, Auteur ; Tobias BANASCHEWSKI, Auteur ; Daniel BRANDEIS, Auteur ; Jan K. BUITELAAR, Auteur ; Ralf W. DITTMANN, Auteur ; Chris HOLLIS, Auteur ; Martin HOLTMANN, Auteur ; Eric KONOFAL, Auteur ; Michel LECENDREUX, Auteur ; Aribert ROTHENBERGER, Auteur ; Paramala SANTOSH, Auteur ; Emily SIMONOFF, Auteur ; Cesar SOUTULLO, Auteur ; Hans Christoph STEINHAUSEN, Auteur ; Argyris STRINGARIS, Auteur ; Eric TAYLOR, Auteur ; Ian C. K. WONG, Auteur ; Alessandro ZUDDAS, Auteur ; Edmund J. S. SONUGA-BARKE, Auteur Article en page(s) : p.932-947 Langues : Anglais (eng) Mots-clés : ADHD behaviour therapy conduct disorder parent training treatment trials Index. décimale : PER Périodiques Résumé : Background Behavioural interventions are recommended for use with children and young people with attention deficit hyperactivity disorder (ADHD); however, specific guidance for their implementation based on the best available evidence is currently lacking. Methods This review used an explicit question and answer format to address issues of clinical concern, based on expert interpretation of the evidence with precedence given to meta-analyses of randomised controlled trials. Results On the basis of current evidence that takes into account whether outcomes are blinded, behavioural intervention cannot be supported as a front-line treatment for core ADHD symptoms. There is, however, evidence from measures that are probably blinded that these interventions benefit parenting practices and improve conduct problems which commonly co-occur with ADHD, and are often the main reason for referral. Initial positive results have also been found in relation to parental knowledge, children's emotional, social and academic functioning ? although most studies have not used blinded outcomes. Generic and specialised ADHD parent training approaches ? delivered either individually or in groups ? have reported beneficial effects. High-quality training, supervision of therapists and practice with the child, may improve outcomes but further evidence is required. Evidence for who benefits the most from behavioural interventions is scant. There is no evidence to limit behavioural treatments to parents with parenting difficulties or children with conduct problems. There are positive effects of additive school-based intervention for the inattentive subtype. Targeting parental depression may enhance the effects of behavioural interventions. Conclusions Parent training is an important part of the multimodal treatment of children with ADHD, which improves parenting, reduces levels of oppositional and noncompliant behaviours and may improve other aspects of functioning. However, blinded evidence does not support it as a specific treatment for core ADHD symptoms. More research is required to understand how to optimise treatment effectiveness either in general or for individual patients and explore potential barriers to treatment uptake and engagement. In terms of selecting which intervention formats to use, it seems important to acknowledge and respond to parental treatment preferences. En ligne : https://doi.org/10.1111/jcpp.12825 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=368
in Journal of Child Psychology and Psychiatry > 59-9 (September 2018) . - p.932-947[article] Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder [Texte imprimé et/ou numérique] / David DALEY, Auteur ; Saskia VAN DER OORD, Auteur ; Maite FERRIN, Auteur ; Samuele CORTESE, Auteur ; Marina DANCKAERTS, Auteur ; Manfred DOEPFNER, Auteur ; Barbara J. VAN DEN HOOFDAKKER, Auteur ; David COGHILL, Auteur ; Margaret THOMPSON, Auteur ; Philip ASHERSON, Auteur ; Tobias BANASCHEWSKI, Auteur ; Daniel BRANDEIS, Auteur ; Jan K. BUITELAAR, Auteur ; Ralf W. DITTMANN, Auteur ; Chris HOLLIS, Auteur ; Martin HOLTMANN, Auteur ; Eric KONOFAL, Auteur ; Michel LECENDREUX, Auteur ; Aribert ROTHENBERGER, Auteur ; Paramala SANTOSH, Auteur ; Emily SIMONOFF, Auteur ; Cesar SOUTULLO, Auteur ; Hans Christoph STEINHAUSEN, Auteur ; Argyris STRINGARIS, Auteur ; Eric TAYLOR, Auteur ; Ian C. K. WONG, Auteur ; Alessandro ZUDDAS, Auteur ; Edmund J. S. SONUGA-BARKE, Auteur . - p.932-947.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 59-9 (September 2018) . - p.932-947
Mots-clés : ADHD behaviour therapy conduct disorder parent training treatment trials Index. décimale : PER Périodiques Résumé : Background Behavioural interventions are recommended for use with children and young people with attention deficit hyperactivity disorder (ADHD); however, specific guidance for their implementation based on the best available evidence is currently lacking. Methods This review used an explicit question and answer format to address issues of clinical concern, based on expert interpretation of the evidence with precedence given to meta-analyses of randomised controlled trials. Results On the basis of current evidence that takes into account whether outcomes are blinded, behavioural intervention cannot be supported as a front-line treatment for core ADHD symptoms. There is, however, evidence from measures that are probably blinded that these interventions benefit parenting practices and improve conduct problems which commonly co-occur with ADHD, and are often the main reason for referral. Initial positive results have also been found in relation to parental knowledge, children's emotional, social and academic functioning ? although most studies have not used blinded outcomes. Generic and specialised ADHD parent training approaches ? delivered either individually or in groups ? have reported beneficial effects. High-quality training, supervision of therapists and practice with the child, may improve outcomes but further evidence is required. Evidence for who benefits the most from behavioural interventions is scant. There is no evidence to limit behavioural treatments to parents with parenting difficulties or children with conduct problems. There are positive effects of additive school-based intervention for the inattentive subtype. Targeting parental depression may enhance the effects of behavioural interventions. Conclusions Parent training is an important part of the multimodal treatment of children with ADHD, which improves parenting, reduces levels of oppositional and noncompliant behaviours and may improve other aspects of functioning. However, blinded evidence does not support it as a specific treatment for core ADHD symptoms. More research is required to understand how to optimise treatment effectiveness either in general or for individual patients and explore potential barriers to treatment uptake and engagement. In terms of selecting which intervention formats to use, it seems important to acknowledge and respond to parental treatment preferences. En ligne : https://doi.org/10.1111/jcpp.12825 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=368 Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers / L. MASON in Molecular Autism, 12 (2021)
[article]
Titre : Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers Type de document : Texte imprimé et/ou numérique Auteurs : L. MASON, Auteur ; F. SHIC, Auteur ; T. FALCK-YTTER, Auteur ; Bhismadev CHAKRABARTI, Auteur ; Tony CHARMAN, Auteur ; E. LOTH, Auteur ; J. TILLMANN, Auteur ; Tobias BANASCHEWSKI, Auteur ; Simon BARON-COHEN, Auteur ; Sven BÖLTE, Auteur ; Jan K. BUITELAAR, Auteur ; S. DURSTON, Auteur ; B. ORANJE, Auteur ; A. M. PERSICO, Auteur ; C. BECKMANN, Auteur ; T. BOUGERON, Auteur ; F. DELL'ACQUA, Auteur ; C. ECKER, Auteur ; C. MOESSNANG, Auteur ; D. MURPHY, Auteur ; M. H. JOHNSON, Auteur ; E. J. H. JONES, Auteur Article en page(s) : 74 p. Langues : Anglais (eng) Mots-clés : Autism Biological motion Biomarker Development Eye tracking in the last 3 years acted as an author, consultant or lecturer for Medice and Roche. He receives royalties for text books and diagnostic tools from Hogrefe, Kohlhammer and UTB. JB has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Index. décimale : PER Périodiques Résumé : BACKGROUND: The neurocognitive mechanisms underlying autism spectrum disorder (ASD) remain unclear. Progress has been largely hampered by small sample sizes, variable age ranges and resulting inconsistent findings. There is a pressing need for large definitive studies to delineate the nature and extent of key case/control differences to direct research towards fruitful areas for future investigation. Here we focus on perception of biological motion, a promising index of social brain function which may be altered in ASD. In a large sample ranging from childhood to adulthood, we assess whether biological motion preference differs in ASD compared to neurotypical participants (NT), how differences are modulated by age and sex and whether they are associated with dimensional variation in concurrent or later symptomatology. METHODS: Eye-tracking data were collected from 486 6-to-30-year-old autistic (N?=?282) and non-autistic control (N?=?204) participants whilst they viewed 28 trials pairing biological (BM) and control (non-biological, CTRL) motion. Preference for the biological motion stimulus was calculated as (1) proportion looking time difference (BM-CTRL) and (2) peak look duration difference (BM-CTRL). RESULTS: The ASD group showed a present but weaker preference for biological motion than the NT group. The nature of the control stimulus modulated preference for biological motion in both groups. Biological motion preference did not vary with age, gender, or concurrent or prospective social communicative skill within the ASD group, although a lack of clear preference for either stimulus was associated with higher social-communicative symptoms at baseline. LIMITATIONS: The paired visual preference we used may underestimate preference for a stimulus in younger and lower IQ individuals. Our ASD group had a lower average IQ by approximately seven points. 18% of our sample was not analysed for various technical and behavioural reasons. CONCLUSIONS: Biological motion preference elicits small-to-medium-sized case-control effects, but individual differences do not strongly relate to core social autism associated symptomatology. We interpret this as an autistic difference (as opposed to a deficit) likely manifest in social brain regions. The extent to which this is an innate difference present from birth and central to the autistic phenotype, or the consequence of a life lived with ASD, is unclear. En ligne : http://dx.doi.org/10.1186/s13229-021-00476-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=459
in Molecular Autism > 12 (2021) . - 74 p.[article] Preference for biological motion is reduced in ASD: implications for clinical trials and the search for biomarkers [Texte imprimé et/ou numérique] / L. MASON, Auteur ; F. SHIC, Auteur ; T. FALCK-YTTER, Auteur ; Bhismadev CHAKRABARTI, Auteur ; Tony CHARMAN, Auteur ; E. LOTH, Auteur ; J. TILLMANN, Auteur ; Tobias BANASCHEWSKI, Auteur ; Simon BARON-COHEN, Auteur ; Sven BÖLTE, Auteur ; Jan K. BUITELAAR, Auteur ; S. DURSTON, Auteur ; B. ORANJE, Auteur ; A. M. PERSICO, Auteur ; C. BECKMANN, Auteur ; T. BOUGERON, Auteur ; F. DELL'ACQUA, Auteur ; C. ECKER, Auteur ; C. MOESSNANG, Auteur ; D. MURPHY, Auteur ; M. H. JOHNSON, Auteur ; E. J. H. JONES, Auteur . - 74 p.
Langues : Anglais (eng)
in Molecular Autism > 12 (2021) . - 74 p.
Mots-clés : Autism Biological motion Biomarker Development Eye tracking in the last 3 years acted as an author, consultant or lecturer for Medice and Roche. He receives royalties for text books and diagnostic tools from Hogrefe, Kohlhammer and UTB. JB has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Takeda/Shire, Roche, Medice, Angelini, Janssen and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties. Index. décimale : PER Périodiques Résumé : BACKGROUND: The neurocognitive mechanisms underlying autism spectrum disorder (ASD) remain unclear. Progress has been largely hampered by small sample sizes, variable age ranges and resulting inconsistent findings. There is a pressing need for large definitive studies to delineate the nature and extent of key case/control differences to direct research towards fruitful areas for future investigation. Here we focus on perception of biological motion, a promising index of social brain function which may be altered in ASD. In a large sample ranging from childhood to adulthood, we assess whether biological motion preference differs in ASD compared to neurotypical participants (NT), how differences are modulated by age and sex and whether they are associated with dimensional variation in concurrent or later symptomatology. METHODS: Eye-tracking data were collected from 486 6-to-30-year-old autistic (N?=?282) and non-autistic control (N?=?204) participants whilst they viewed 28 trials pairing biological (BM) and control (non-biological, CTRL) motion. Preference for the biological motion stimulus was calculated as (1) proportion looking time difference (BM-CTRL) and (2) peak look duration difference (BM-CTRL). RESULTS: The ASD group showed a present but weaker preference for biological motion than the NT group. The nature of the control stimulus modulated preference for biological motion in both groups. Biological motion preference did not vary with age, gender, or concurrent or prospective social communicative skill within the ASD group, although a lack of clear preference for either stimulus was associated with higher social-communicative symptoms at baseline. LIMITATIONS: The paired visual preference we used may underestimate preference for a stimulus in younger and lower IQ individuals. Our ASD group had a lower average IQ by approximately seven points. 18% of our sample was not analysed for various technical and behavioural reasons. CONCLUSIONS: Biological motion preference elicits small-to-medium-sized case-control effects, but individual differences do not strongly relate to core social autism associated symptomatology. We interpret this as an autistic difference (as opposed to a deficit) likely manifest in social brain regions. The extent to which this is an innate difference present from birth and central to the autistic phenotype, or the consequence of a life lived with ASD, is unclear. En ligne : http://dx.doi.org/10.1186/s13229-021-00476-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=459 Pupil Dilation Progression Modulates Aberrant Social Cognition in Autism Spectrum Disorder / Nico BAST in Autism Research, 12-11 (November 2019)
PermalinkResting state EEG power spectrum and functional connectivity in autism: a cross-sectional analysis / Pilar GARCES in Molecular Autism, 13 (2022)
PermalinkSaccade dysmetria indicates attenuated visual exploration in autism spectrum disorder / Nico BAST in Journal of Child Psychology and Psychiatry, 62-2 (February 2021)
PermalinkSensory salience processing moderates attenuated gazes on faces in autism spectrum disorder: a case-control study / Luke MASON ; Christine ECKER ; Sarah BAUMEISTER ; Tobias BANASCHEWSKI ; Emily J. H. JONES ; Declan G. M. MURPHY ; Jan K. BUITELAAR ; Eva LOTH ; Gahan PANDINA ; Christine M. FREITAG in Molecular Autism, 14 (2023)
PermalinkSleep patterns in children with attention-deficit/hyperactivity disorder, tic disorder, and comorbidity / Roumen KIROV in Journal of Child Psychology and Psychiatry, 48-6 (June 2007)
PermalinkSocial brain activation during mentalizing in a large autism cohort: the Longitudinal European Autism Project / Carolin MOESSNANG in Molecular Autism, 11 (2020)
PermalinkStructural brain correlates of adolescent resilience / Keith B. BURT in Journal of Child Psychology and Psychiatry, 57-11 (November 2016)
PermalinkThe Child Behavior Checklist-Dysregulation Profile predicts substance use, suicidality, and functional impairment: a longitudinal analysis / Martin HOLTMANN in Journal of Child Psychology and Psychiatry, 52-2 (February 2011)
PermalinkThe EU-AIMS Longitudinal European Autism Project (LEAP): clinical characterisation / Tony CHARMAN in Molecular Autism, 8 (2017)
PermalinkThe EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders / E. LOTH in Molecular Autism, 8 (2017)
Permalink